NGS Cancer Hotspot Panel

Background

Accredited testing is now available using the AmpliSeq for Illumina Cancer Hotspot Panel v2. 

The following genes are partially sequenced in this test: ABL1, AKT1, ALK, APC, ATM, BRAF, CDH1, CDKN2A, CSF1R, CTNNB1, EGFR, ERBB2, ERBB4, EZH2, FBXW7, FGFR1, FGFR2, FGFR3, FLT3, GNA11, GNAQ, GNAS, HNF1A, HRAS, IDH1, IDH2, JAK2, JAK3, KDR, KIT, KRAS, MET, MLH1, MPL, NOTCH1, NPM1, NRAS, PDGFRA, PIK3CA, PTEN, PTPN11, RB1, RET, SMAD4, SMARCB1, SMO, SRC, STK11, TP53, VHL

For more information about the coverage of the genes and transcripts included in this assay please click this link
 

NGS Cancer Hotspot Panel Testing at WRGL

NGS testing is performed using a commercially available kit from Illumina (https://sapac.illumina.com/products/by-type/sequencing-kits/library-prep-kits/ampliseq-cancer-hotspot-panel.html) followed by analysis on a iSeq 100 Sequencing System.  This is a targeted NGS assay used to sequence ~2,800 COSMIC somatic mutations across hotspot regions of 50 genes with known associations to cancer.

 

Cost, Sample Requirements & Turnaround Times

 

Test	Cost NZD*	Sample Requirements	Current TAT
Cancer Hotspot Panel	$693 + GST	NGS testing can be performed on bone marrow, leukaemic blood and FFPE samples Bone Marrow: 1-10ml in EDTA Leukaemic Blood: 4-10ml in EDTA FFPE sample:  please provide 2-3 slides (minimum) cut at 4 microns along with an H&E slide with the area of interest circled	4 weeks

 
*No direct charge for the central region DHBs covered by the Crown Funding Agreement